Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 58, Issue 2, Pages 833-838Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01896-13
Keywords
-
Categories
Funding
- Cerexa, Inc.
- Forest Research Institute, Inc.
- Aires
- American Proficiency Institute (API)
- Anacor
- Astellas
- AstraZeneca
- Bayer
- bioMerieux
- Cempra
- Cerexa
- Contrafect
- Cubist
- Dipexium
- Furiex
- GlaxoSmithKline
- Johnson Johnson
- LegoChem Biosciences, Inc.
- Meiji Seika Kaisha
- Merck
- Nabriva
- Novartis
- Pfizer
- PPD Therapeutics
- Premier Research Group
- Rempex
- Rib-X Pharmaceuticals
- Seachaid
- Shionogi
- Medicines Co.
- Theravance
- Thermo-Fisher Scientific
Ask authors/readers for more resources
Escherichia coli (328 isolates), Klebsiella pneumoniae (296), Klebsiella oxytoca (44), and Proteus mirabilis (33) isolates collected during 2012 from the nine U.S. census regions and displaying extended-spectrum-beta-lactamase (ESBL) phenotypes were evaluated for the presence of beta-lactamase genes, and antimicrobial susceptibility profiles were analyzed. The highest ESBL rates were noted for K. pneumoniae (16.0%, versus 4.8 to 11.9% for the other species) and in the Mid-Atlantic and West South Central census regions. CTX-M group 1 (including CTX-M-15) was detected in 303 strains and was widespread throughout the United States but was more prevalent in the West South Central, Mid-Atlantic, and East North Central regions. KPC producers (118 strains [112 K. pneumoniae strains]) were detected in all regions and were most frequent in the Mid-Atlantic region (58 strains). Thirteen KPC producers also carried blaCTX-M. SHV genes encoding ESBL activity were detected among 176 isolates. Other beta-lactamase genes observed were CTX-M group 9 (72 isolates), FOX (10), TEM ESBL (9), DHA (7), CTX-M group 2 (3), NDM-1 (2 [Colorado]), and CTX-M groups 8 and 25 (1). Additionally, 62.9% of isolates carried >= 2 beta-lactamase genes. KPC producers were highly resistant to multiple agents, but ceftazidime-avibactam (MIC50/90, 0.5/2 mu g/ml) and tigecycline (MIC50/90, 0.5/1 mu g/ml) were the most active agents tested. Overall, meropenem (MIC50, <= 0.06 mu g/ml), ceftazidime-avibactam (MIC50, 0.12 to 0.5 mu g/ml), and tigecycline (MIC50, 0.12 to 2 mu g/ml) were the most active antimicrobials when tested against this collection. NDM-1 producers were resistant to all beta-lactams tested. The diversity and increasing prevalence of beta-lactamase-producing Enterobacteriaceae have been documented, and ceftazidime-avibactam was very active against the vast majority of beta-lactamase-producing strains isolated from U.S. hospitals.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available